Screener
Rigel Pharmaceuticals RIGL Single reportable segment — Commercial related expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept rigl:CommercialRelatedExpenses.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total Revenues | $58,818 | $53,333 |
| Less: | ||
| Employee related expenses | 21,002 | 19,538 |
| Commercial related expenses | 7,040 | 5,339 |
| Outside clinical trial related expenses | 6,927 | 4,371 |
| Cost of product sales | 4,606 | 4,409 |
| Consultants and third-party services | 4,006 | 3,409 |
| Other segment items | 3,352 | 3,494 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's single reportable segment — commercial related expenses?
- Rigel Pharmaceuticals (RIGL) reported single reportable segment — commercial related expenses of $7.04M in Q1 2026.
- What does single reportable segment — commercial related expenses mean?
- Captures the costs incurred for marketing, sales force support, and commercialization activities for the company's pharmaceutical products. This metric indicates the level of investment required to drive market adoption and product awareness.
Ask your AI about Rigel Pharmaceuticals's single reportable segment — commercial related expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude